The same drug that can help anesthetize a patient during surgery can ease depression symptoms within hours in some people. That contrast explains why so many readers ask, “what does ketamine do to your brain?” Ketamine can quickly change perception and awareness, but its medical value reaches beyond that unusual experience. Understanding its effects means looking at how treatment setting, medical history, and patterns of use change the outcome.
The United States Food and Drug Administration first approved ketamine as an anesthetic in 1970. Today, clinicians also use it in selected pain and mental health settings, while nonmedical use creates a different set of risks. This guide separates established effects from leading theories and explains mood benefits, memory changes, dependence, and possible long-term harm. It also covers what supervised treatment looks like, how alternatives compare, and which claims deserve skepticism.
How Ketamine Changes Brain Function
Ketamine temporarily changes how brain cells communicate, mainly by blocking a glutamate receptor involved in learning, memory, pain, and perception. This can produce dissociation, sedation, and pain relief, while certain medical treatment plans can also reduce depression symptoms. Glutamate acts as a major signaling messenger, not a simple happiness chemical. For example, someone receiving ketamine for a painful procedure may feel detached from the room and later remember little of the experience.
From Anesthetic to Dissociative Medicine
Chemist Calvin Stevens first synthesized ketamine in 1962, and researchers began human testing in 1964. Scientists sought an anesthetic with practical advantages over older drugs, including phencyclidine. Ketamine became known as a dissociative anesthetic because it can disconnect awareness from sensations, surroundings, and the usual sense of self. Dissociation differs from ordinary sleep, even when a person seems quiet or unresponsive.
Unlike many anesthetics, ketamine often preserves spontaneous breathing and some airway reflexes when clinicians use it alone. That feature helps explain its role in emergency departments, including certain pediatric procedures. However, preserved breathing is not guaranteed, and airway obstruction, vomiting, aspiration, or dangerous sedation can still occur. A patient who keeps their eyes open may remain deeply disconnected from the surroundings and still need close monitoring.
Ketamine, Esketamine, and Other Forms
Standard ketamine contains two mirror-image molecular forms, called R-ketamine and S-ketamine. Scientists call this mixture racemic ketamine, while esketamine contains only the S form. The prescription nasal spray Spravato contains esketamine rather than the racemic mixture. Clinicians also administer ketamine through intravenous or intramuscular routes, and some prescribers use compounded oral or nasal products. These products differ in absorption, supporting evidence, approved uses, and medical oversight.
A clinic infusion, a regulated nasal spray, and an at-home compounded lozenge are not interchangeable treatments. For example, swallowing a medicine sends it through the digestive system and liver before much of it reaches the bloodstream. A pharmacy-made ketamine lozenge does not gain approval for depression simply because ketamine has an anesthetic approval. Ketamine also differs from classic psychedelics such as psilocybin, which primarily act through a serotonin receptor rather than ketamine’s main glutamate target.
The Glutamate Pathway and Brain Plasticity
Ketamine’s best-established molecular action involves blocking the N-methyl-D-aspartate receptor, one type of glutamate receptor. A receptor works like a receiving station that helps a nerve cell respond to a chemical message. These receptors help regulate memory formation, pain signaling, and changes in the strength of connections between cells. However, identifying this target does not fully explain why one patient experiences mood relief while another mainly experiences dizziness or detachment.
How a Brief Exposure May Produce Longer Effects
One leading theory starts with inhibitory neurons, which act like part of the brain’s braking system. Blocking certain receptors on these cells may briefly release some of that braking and change glutamate activity in nearby circuits. Other glutamate receptors can then help trigger processes that strengthen or reshape connections between neurons. Much of this detailed explanation comes from animal and laboratory research, so scientists do not treat every step as a settled account of human recovery.
- Ketamine blocks selected glutamate receptors and changes signaling within affected brain circuits.
- In some circuits, reduced inhibition may produce a brief increase in glutamate signaling.
- Other glutamate receptors respond and help activate pathways involved in adapting connections between nerve cells.
- Those downstream changes may last after ketamine levels fall, offering one explanation for longer-lasting mood effects.
Researchers connect these processes with brain-derived neurotrophic factor, a protein that supports the health and adaptability of nerve cells. A 2019 study by Moda-Sava and colleagues in Science tracked changes in tiny connection points called dendritic spines in mice after ketamine. The findings suggested that new spine formation helped sustain certain behavioral improvements rather than explain their earliest onset. This distinction matters because rapid symptom relief and longer-term recovery may involve different processes. It also shows why calling ketamine an instant brain-repair drug goes beyond the evidence.
Why the Brain Reset Story Falls Short
Brain-imaging studies show that ketamine can change communication within and between large networks. These include the default mode network, which researchers connect with self-focused thinking and mental activity during rest. A person who usually gets stuck in harsh self-criticism might experience a temporary change in that pattern, but a scan cannot directly read those thoughts. Imaging measures such as blood-flow changes also do not prove that a network has returned to a single ideal setting.
A small 2018 study in the American Journal of Psychiatry suggested that blocking opioid receptors could weaken ketamine’s antidepressant effect. Later research has not settled how much this system contributes across different patients and treatment conditions. Scientists also study ketamine’s breakdown products, including hydroxynorketamine, as possible contributors to its effects. These findings make a one-receptor, one-outcome explanation too simple, but they do not make ketamine a standard opioid drug.
What You May Feel During and After Ketamine
Ketamine can alter experience within minutes, especially when a clinician administers it intravenously. People may notice that sounds seem distant, time moves strangely, or their body feels unusually light or heavy. Someone lying in a treatment chair might feel as though they are watching the room from far away while still recognizing that they are receiving medicine. The exact experience varies, and a dramatic session does not guarantee a strong medical benefit.
Dissociation, Perception, and Short-Term Memory
Dissociation can range from mild detachment to a profound loss of normal awareness of the body and surroundings. Some people describe the experience as calm, while others experience fear, confusion, or disturbing images. People sometimes call intense detachment a k-hole, but that slang term does not define a medical treatment goal. A clinical team aims to support the patient and manage adverse effects, not push everyone toward the most intense experience possible.
Ketamine can also interfere with attention and the brain’s ability to record new memories during its active effects. For example, a patient may remember entering the clinic but have patchy recall of conversations during treatment. These temporary memory gaps do not by themselves prove permanent brain injury. However, they do make it important to review consent, transportation plans, and major decisions before treatment rather than during an altered state.
Why the Experience and Mood Benefit Have Different Timelines
Ketamine’s elimination half-life in adults is roughly 2 to 3 hours, although the exact value varies with the person and treatment conditions. Half-life means the time needed for the body to reduce the drug amount by about half, not the time until every effect disappears. Metabolites, other medicines, and individual differences can extend impairment or change recovery. Mood improvement, when it occurs, may outlast the most noticeable dissociation because downstream brain processes follow a different timeline.
| Stage | Possible Changes | What the Changes Do Not Prove |
|---|---|---|
| During treatment | Detachment, altered perception, dizziness, sedation, or nausea | A stronger experience does not establish greater antidepressant benefit. |
| First several hours | Gradual recovery, sometimes with fatigue or reduced coordination | Feeling less detached does not automatically make driving safe. |
| Later that day or the next day | Some patients notice mood improvement; others do not | A single day’s result does not determine the full treatment outcome. |
| Following days or weeks | Benefits may continue, weaken, or require an ongoing care plan | Temporary relief does not establish a permanent cure. |
Ketamine also affects the body outside the brain, often raising blood pressure and heart rate for a period after administration. A person may feel emotionally calm while a monitor shows a clinically important blood pressure increase. Nausea, headache, blurred vision, and poor coordination can also occur, especially around the treatment session. This mismatch between how someone feels and what their body is doing explains why medical monitoring cannot rely on conversation alone.
Depression Benefits and How Treatment Compares
Ketamine matters in psychiatry because some people experience relief much faster than they do with standard antidepressants. Treatment-resistant depression often means depression that has not improved enough after at least two adequate antidepressant trials, although definitions vary. Before using that label, clinicians should review the diagnosis, treatment duration, adherence, and conditions such as bipolar disorder. For example, two brief medication attempts stopped because of side effects do not necessarily provide the same information as two completed treatment trials.
What Clinical Trials and Approvals Show
A 2006 trial led by Carlos Zarate at the National Institute of Mental Health enrolled 18 people with treatment-resistant depression. Researchers found antidepressant effects within 110 minutes after a monitored ketamine infusion, with meaningful differences from placebo at 24 hours. This small study helped launch modern interest in rapid-acting antidepressants, but it did not establish lifelong benefit. Later trials supported short-term benefit for some patients while also showing that others do not respond. Many responders need additional treatment because improvement after a single administration can fade over days to weeks.
The Food and Drug Administration approved Spravato for treatment-resistant depression in adults in 2019. In January 2025, the agency expanded that use to allow treatment alone or with an oral antidepressant. Spravato also has a separate indication, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior. These approvals apply to a specific intranasal product and supervised treatment program. The agency has not approved intravenous racemic ketamine for depression, so clinicians who prescribe it for that purpose use it off-label.
Ketamine Versus Other Treatments
A 2023 trial in The New England Journal of Medicine compared ketamine with electroconvulsive therapy in 403 adults with nonpsychotic treatment-resistant major depression. During the initial 3-week treatment phase, response rates reached 55.4 percent with ketamine and 41.2 percent with electroconvulsive therapy. The trial met its planned standard for showing that ketamine was not substantially less effective in that particular population. However, it used an open-label design, meaning patients and clinicians knew which treatment they received. The findings do not establish ketamine as the best choice for psychotic depression, catatonia, or every patient needing urgent care.
Medicines such as sertraline usually take several weeks to deliver their main antidepressant benefit, but they have extensive evidence for ongoing outpatient treatment. Transcranial magnetic stimulation offers another option through repeated treatment sessions that generally do not require anesthesia. Psychotherapy can address patterns of thinking, relationships, trauma, and behavior that a brief medication effect may not resolve. In bipolar depression, clinicians also need to assess the possibility of mania or hypomania and consider the broader mood-stabilizing treatment plan. The useful comparison is not simply which treatment acts fastest, but which approach best matches the person’s diagnosis, risks, and long-term needs.
Ketamine can reduce suicidal thoughts quickly in some research settings, but reducing a symptom is not the same as proving that a treatment prevents suicide. The Spravato prescribing information specifically states that its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. For example, a patient who feels less hopeless after treatment may still need hospital care, a safety plan, and close follow-up. A promising early response should support comprehensive care rather than replace it.
Memory, Dependence, and Risks of Repeated Use
The brain risks of one monitored procedure differ from those of frequent, prolonged nonmedical use. A patient receiving a limited course with follow-up does not have the same exposure pattern as someone using ketamine daily while also drinking heavily. At the same time, medical supervision does not make every repeated-use risk disappear. Understanding long-term effects requires separating temporary impairment, persistent symptoms, animal findings, and human studies with different treatment schedules.
What Long-Term Studies Can and Cannot Tell Us
A 2010 study in Addiction by Morgan and colleagues followed ketamine users and comparison groups over one year. Frequent use was associated with poorer memory and other concerning cognitive and psychological outcomes. Such studies raise real concerns, but they cannot cleanly separate every effect of ketamine from other drug use, sleep loss, mental health conditions, or lifestyle factors. Brain-imaging studies have also reported differences in heavy long-term users. Those differences do not allow a clinician to look at one scan and determine exactly how much injury ketamine caused or whether every change will persist.
Clinical studies of supervised esketamine have generally not shown the same pattern of cognitive problems reported among heavy nonmedical users. However, long-term extension studies often lack a blinded comparison group, and participants may differ from people treated outside research settings. For example, a trial may exclude patients with certain substance use disorders or unstable medical illnesses. Reassuring findings therefore support careful medical use within studied conditions, not a claim that unlimited exposure carries no cognitive risk.
Animal experiments can produce signs of nerve-cell injury under certain exposure conditions, especially in developing brains. Researchers use these findings to identify possible hazards, but animal age, drug exposure, and physiology do not map neatly onto adult clinical treatment. A result in a young rodent cannot establish that a monitored adult infusion causes the same damage. It also cannot settle safety questions for pregnancy, childhood development, or years of repeated psychiatric treatment.
Tolerance, Addiction, and Whole-Body Harm
Ketamine can produce tolerance, meaning a person needs more exposure to get an effect they previously experienced with less. It can also cause a substance use disorder marked by craving, loss of control, and continued use despite harm. For example, someone might begin missing work or spending money needed for rent while repeatedly trying and failing to cut back. Frequent users who stop may experience craving, low mood, anxiety, sleep problems, and sometimes physical symptoms. An addiction specialist can assess the need for support, especially when alcohol, opioids, or sedatives are also involved.
Some of ketamine’s most serious repeated-use harms occur outside the brain, particularly in the bladder and urinary tract. Ketamine-associated cystitis can cause frequent urination, pelvic pain, urgency, and blood in the urine. A person who starts needing the bathroom every 20 minutes should not dismiss the change as an inconvenience or simply increase fluid intake and continue using. Severe cases can involve a shrunken bladder or damage farther up the urinary tract, and repeated exposure can also harm the liver or bile ducts. Stopping nonmedical ketamine use and obtaining medical assessment can limit further harm, although recovery may remain incomplete.
- Ask a clinician to assess persistent urinary symptoms rather than assuming they represent an ordinary infection.
- Get prompt medical care for new upper abdominal pain or yellowing of the skin, which can signal liver or bile duct trouble.
- Seek addiction support when use continues despite harm rather than trying to manage cravings with more ketamine.
What Safer Medical Treatment Looks Like
Medical ketamine treatment involves more than giving a drug and providing a comfortable chair. A responsible service reviews the diagnosis, checks health risks, monitors the session, and plans follow-up. In 2023, the Food and Drug Administration warned about risks linked to compounded ketamine products used for psychiatric disorders, including at-home use without onsite monitoring. Compounding can serve legitimate medical needs, but it does not establish that a product has the same evidence or safeguards as an approved medicine.
Screening Health Conditions and Medication Interactions
Before treatment, a clinician should review blood pressure, heart and blood vessel disease, mental health history, substance use, and current medicines. For example, the Spravato label lists aneurysmal blood vessel disease and a history of bleeding inside the brain among its contraindications. Poorly controlled hypertension, psychosis, or recent mania may make treatment unsuitable or require specialist assessment. A history of substance use disorder does not automatically settle eligibility, but it makes assessment and monitoring especially important. Pregnancy, breastfeeding, and psychiatric treatment in teenagers require additional caution because adult depression studies cannot establish safety for these groups. In particular, clinicians should not treat ketamine’s established pediatric anesthesia role as proof that repeated psychiatric treatment is appropriate for children.
Alcohol, opioids, benzodiazepines, and other sedating medicines can increase sedation or breathing risks when combined with ketamine. Examples include oxycodone, diazepam, and some sleep medicines. Stimulants and certain other psychiatric drugs can also affect blood pressure during treatment, so a complete medication list matters. Researchers continue to examine whether some medicines change ketamine’s antidepressant response, but patients should not stop prescribed drugs on their own to strengthen the experience. Abruptly stopping a benzodiazepine or changing a mood stabilizer can create risks unrelated to ketamine itself.
Monitoring, Recovery, and Warning Signs
In the United States, Spravato requires administration under supervision through a restricted safety program, with monitoring for at least 2 hours after each treatment. Staff assess blood pressure, sedation, dissociation, and respiratory status, including pulse oximetry. They must also determine whether the person is clinically stable enough to leave, rather than treating 2 hours as an automatic discharge time. Intravenous ketamine protocols differ, but trained staff and equipment for managing medical complications remain important. For example, someone attending a Monday morning appointment should arrange transportation rather than plan to drive home after lunch. Spravato instructions advise against driving or operating machinery until the next day after a restful sleep, and persistent impairment can require longer restrictions.
Call emergency services for slow or difficult breathing, a seizure, chest pain, or an inability to wake someone after ketamine. Stay with the person and tell responders what they may have taken, including alcohol or opioids. In the United States and Canada, call or text 988 for a suicidal or emotional crisis. If someone faces immediate danger, use the local emergency number rather than waiting for a clinic reply.
Pain, Trauma, and Other Uses Under Study
Ketamine’s role extends beyond depression, but the strength of evidence changes with the condition. An emergency physician using it for a painful procedure works toward a different goal than a psychiatrist treating a long depressive episode. Likewise, reducing pain after surgery does not prove that repeated ketamine will help every chronic pain condition. Readers should ask which diagnosis a study examined, what outcome improved, and how long that improvement lasted.
Pain Relief and Nervous System Sensitization
Glutamate receptors help the nervous system amplify pain signals, a process that can contribute to central sensitization. Ketamine can interrupt parts of that signaling, which explains interest in conditions such as complex regional pain syndrome. Consensus guidelines published in Regional Anesthesia and Pain Medicine in 2018 reviewed its role in chronic pain and emphasized that evidence varies by diagnosis. Some patients gain relief, but the best-supported schedules and the durability of benefit remain uncertain for several conditions. Pain treatment also requires attention to physical function, rehabilitation, sleep, and the cause of the pain.
In hospital care, clinicians sometimes use ketamine alongside other pain medicines to reduce opioid requirements. For example, a surgical team may consider it for a patient with difficult postoperative pain and substantial opioid tolerance. That approach does not mean the person should replace prescribed pain treatment with unsupervised ketamine. A useful outcome includes better movement, breathing, sleep, or rehabilitation, not simply feeling detached from pain during administration.
Trauma, Anxiety, and Substance Use Research
A 2021 randomized trial in the American Journal of Psychiatry studied 30 adults with chronic post-traumatic stress disorder and found greater symptom improvement with ketamine than with midazolam. However, larger research in military populations has produced mixed or negative results on the main trauma outcome. These differences mean ketamine does not hold the same established role in trauma treatment that it holds in anesthesia. For a veteran with nightmares and avoidance, trauma-focused psychotherapy and other evidence-based care still deserve a central place in treatment planning.
Early trials also examine obsessive-compulsive disorder, certain anxiety disorders, and alcohol use disorder. Some studies combine ketamine with counseling or other structured support, which makes the complete treatment package important. For example, an alcohol treatment study that pairs ketamine with counseling cannot answer every question about ketamine taken without that support. A small proof-of-concept trial should prompt further research rather than a clinic claim that one treatment cures several unrelated diagnoses.
Ketamine-assisted psychotherapy pairs drug treatment with psychological preparation, support, or follow-up discussion. A person may feel more open to discussing grief after a session, but that experience alone does not prove lasting recovery. Researchers still need better comparisons to establish which therapy methods add benefit, for whom, and at what stage of treatment. Because patients may feel vulnerable or suggestible during altered states, clear boundaries and advance consent matter, and unusual images or memories do not provide reliable proof of past events.
Choosing Care and Understanding What Comes Next
A beginner may ask whether ketamine works, while a specialist asks which product, which diagnosis, which outcome, and which follow-up period the evidence supports. Both perspectives matter when evaluating a clinic or deciding whether to discuss treatment with a regular clinician. For example, a claim of an 80 percent success rate tells you little unless the clinic explains how it defines success and counts people who stop treatment. Clear information should come before a large payment or a commitment to a long treatment package.
Questions Worth Asking Before You Start
A qualified treatment team should explain who makes the diagnosis, who prescribes, who monitors each session, and who handles emergencies. A psychiatrist, anesthesiologist, or another appropriately qualified clinician may play different roles depending on the setting and the reason for treatment. Ask how the service communicates with your usual mental health or primary care team, particularly if several clinicians prescribe medicines. A clinic that discourages outside medical input or guarantees a cure deserves extra scrutiny.
Agree on measurable goals before the first session rather than relying only on how unusual the experience feels. The Patient Health Questionnaire-9 offers one common way to track depressive symptoms, while direct questions about safety and daily function add essential context. For example, useful goals might include returning to part-time work, sleeping on a steadier schedule, or becoming able to participate in therapy. For repeated treatment, clinicians may also track cognitive concerns, urinary symptoms, blood pressure, and signs of problematic use.
- Ask which evidence supports this treatment for your specific diagnosis.
- Clarify whether the proposed product and use have regulatory approval or involve off-label prescribing.
- Request a plan for reviewing benefit, stopping ineffective treatment, and managing symptom return.
- Find out how the team handles medical complications and psychiatric worsening between appointments.
- Review the full financial cost, including follow-up, maintenance visits, transportation, and time away from work.
The Next Questions for Ketamine Research
One major research challenge involves blinding, because ketamine’s noticeable effects can reveal who received the active drug. A 2023 study in Nature Mental Health attempted to address this issue by giving ketamine or placebo to 40 patients with depression during surgical anesthesia. It did not show a clear antidepressant advantage for ketamine under those conditions. However, surgery, anesthesia, and the small sample limit how directly researchers can apply that result to ordinary outpatient treatment. The study highlights a real debate about expectancy effects without erasing the wider clinical evidence.
Researchers are studying arketamine, which contains the other molecular form, as well as breakdown products such as hydroxynorketamine. They want to know whether future treatments can preserve mood benefits while reducing dissociation, sedation, or misuse risk. Work on brain scans and blood markers may eventually help predict response, but no routine test can currently tell a patient that ketamine will work. A colorful brain scan in a clinic brochure is not proof that an individual’s brain needs ketamine.
For reliable updates, start with the National Institute of Mental Health, Food and Drug Administration safety communications, and the prescribing information available through DailyMed. MedlinePlus also provides patient-friendly drug information that can help explain side effects and precautions. Ask clinics for the full study behind a claim, not just a testimonial, a conference slide, or a percentage without context. Approval rules and clinical standards differ across countries, so confirm which guidance applies where you receive care.
Questions Readers Ask About Ketamine and the Brain
What Does Ketamine Do to Your Brain During Treatment?
Ketamine changes signaling between brain cells, which can cause dissociation, reduce pain, and sometimes lift depression symptoms rapidly. Its main target is a glutamate receptor involved in memory and perception, not simply serotonin. For example, a person may feel detached during a session but notice mood improvement later.
What Does Ketamine Do to Your Brain After Repeated Use?
Repeated ketamine exposure can lead to tolerance and, with frequent nonmedical use, problems with memory, attention, and dependence. Supervised medical treatment has a different risk profile, but researchers still need better long-term comparisons. A 2010 study in Addiction linked frequent use to worse cognitive outcomes, without proving that ketamine alone caused every difference.
How Long Does Ketamine Stay in Your Brain?
Ketamine moves out of brain tissue and undergoes metabolism over hours, but no single time predicts complete recovery for everyone. Its elimination half-life is roughly 2 to 3 hours in adults, while metabolites and downstream effects can last longer. Follow clinical recovery instructions rather than using drug clearance estimates to decide when driving is safe.
Does Ketamine Work Faster Than Antidepressants for Depression?
Ketamine can relieve depression symptoms within hours or a day, while common antidepressants usually need several weeks for meaningful benefit. Faster does not mean more effective or safer for everyone, and benefits may fade without follow-up. For treatment-resistant depression, a clinician weighs prior medication trials, medical risks, access, and longer-term options.
Can Ketamine Cause Permanent Brain Damage?
Heavy, prolonged nonmedical ketamine use is associated with cognitive problems and brain-imaging differences, but these findings do not prove that every change represents permanent injury. Medical studies establish neither that supervised treatment always damages the brain nor that it carries no risk. For example, memory problems that disrupt work deserve medical review.
Do You Have to Dissociate for Ketamine to Work?
You do not need an intense dissociative experience for ketamine to help depression, and stronger detachment does not reliably predict greater benefit. Researchers have found mixed links between session experiences and later symptom improvement. For example, mild perceptual changes do not automatically mean a monitored treatment failed, and chasing a stronger effect adds risk.
Can You Drive the Day After Ketamine Treatment?
After Spravato treatment, you should not drive until the next day after a restful sleep, and only when you feel fully alert. Other ketamine protocols may require different or longer restrictions, so follow your clinician’s instructions. If dizziness, slowed thinking, or poor coordination continues, arrange another ride rather than assuming the calendar makes driving safe.
Putting Ketamine’s Brain Effects in Perspective
Ketamine changes glutamate signaling and can quickly alter awareness, memory formation, pain processing, and mood. Its ability to help some people with difficult-to-treat depression makes it medically valuable, but scientists still debate parts of its longer-lasting action. A monitored treatment course and daily nonmedical use carry different risk profiles, and neither deserves an oversimplified label of completely safe or inevitably damaging. The most useful explanation separates short-term dissociation, possible therapeutic benefit, and the harms that can develop with repeated exposure.
If you are considering treatment, discuss your diagnosis, medical history, medicines, and goals with a qualified clinician before choosing a product or clinic. Resources such as DailyMed prescribing information can help you prepare specific questions about monitoring, recovery, and follow-up. This article provides education rather than a personal diagnosis or treatment plan. With realistic expectations and coordinated care, you can make a better-informed decision about whether ketamine belongs in your treatment options.
